Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
neoPICD: Neoadjuvant Inetetamab and Pyrotinib for HER2+ Breast Cancer
NCT06234137Recruiting
- Start
- Nov 2021
- Primary completion
- Jul 2025
- Modality
- Fragment-Derived Small Molecules, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Open-label, single-arm trial of inetetamab and pyrotinib in HER2-positive breast cancer. Primary endpoint: Total Pathologic Complete Response at 5 months. Started Nov 2021; status: recruiting.
02
Drugs
inetetamabpyrotinib
03
Conditions
HER2-positive breast cancer
Beyond the preview
Go deeper on NCT06234137.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06234137.